Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report

Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic my...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Haa-Na, Kang, Min Gyu, Park, Jeong Rang, Hwang, Jin-Yong, Kang, Jung Hun, Lee, Won Seop, Lee, Gyeong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192916/
https://www.ncbi.nlm.nih.gov/pubmed/29361819
http://dx.doi.org/10.4143/crt.2017.529
_version_ 1783363974546325504
author Song, Haa-Na
Kang, Min Gyu
Park, Jeong Rang
Hwang, Jin-Yong
Kang, Jung Hun
Lee, Won Seop
Lee, Gyeong-Won
author_facet Song, Haa-Na
Kang, Min Gyu
Park, Jeong Rang
Hwang, Jin-Yong
Kang, Jung Hun
Lee, Won Seop
Lee, Gyeong-Won
author_sort Song, Haa-Na
collection PubMed
description Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
format Online
Article
Text
id pubmed-6192916
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-61929162018-10-24 Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report Song, Haa-Na Kang, Min Gyu Park, Jeong Rang Hwang, Jin-Yong Kang, Jung Hun Lee, Won Seop Lee, Gyeong-Won Cancer Res Treat Case Report Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma. Korean Cancer Association 2018-10 2018-01-22 /pmc/articles/PMC6192916/ /pubmed/29361819 http://dx.doi.org/10.4143/crt.2017.529 Text en Copyright © 2018 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Song, Haa-Na
Kang, Min Gyu
Park, Jeong Rang
Hwang, Jin-Yong
Kang, Jung Hun
Lee, Won Seop
Lee, Gyeong-Won
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title_full Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title_fullStr Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title_full_unstemmed Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title_short Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
title_sort pembrolizumab for refractory metastatic myxofibrosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192916/
https://www.ncbi.nlm.nih.gov/pubmed/29361819
http://dx.doi.org/10.4143/crt.2017.529
work_keys_str_mv AT songhaana pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT kangmingyu pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT parkjeongrang pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT hwangjinyong pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT kangjunghun pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT leewonseop pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport
AT leegyeongwon pembrolizumabforrefractorymetastaticmyxofibrosarcomaacasereport

Ejemplares similares